Top Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Companies, Leaders & Major Players

This list of the top companies of Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist is drawn from assessments by Mordor Intelligence analysts and expert advisors via their extensive research to identify the brands, leaders and major players active in Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist sector.

Top Insulin Drugs And Glucagon Like Peptide 1 (GLP 1) Receptor Agonist Companies in Europe

  1. Sanofi

  2. Eli Lilly and Company

  3. Novo Nordisk

  4. AstraZeneca

  5. Biocon

*Disclaimer: Top companies sorted in no particular order

Europe Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Major Players

Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist - Competitive Concentration

Europe Insulin Drugs and Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Market Concentration

List of Insulin Drugs And Glucagon Like Peptide 1 (GLP 1) Receptor Agonist Companies in Europe

  • Novo Nordisk

  • Sanofi

  • Eli Lilly and Company

  • AstraZeneca

  • Biocon

  • Pfizer

  • Wockhardt

  • Julphar

  • Exir

  • Sedico

Get more insights on Europe Insulin Drugs And Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist industry from our comprehensive report

Complete your form and get your market insights delivered to your inbox

Takes less than 10 seconds